RT Journal Article
SR Electronic
T1 MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 697
OP 701
DO 10.1136/jclinpath-2014-202352
VO 67
IS 8
A1 Augello, Claudia
A1 Gianelli, Umberto
A1 Savi, Federica
A1 Moro, Alessia
A1 Bonoldi, Emanuela
A1 Gambacorta, Marcello
A1 Vaira, Valentina
A1 Baldini, Luca
A1 Bosari, Silvano
YR 2014
UL http://jcp.bmj.com/content/67/8/697.abstract
AB Aims To identify molecular characteristics to hepatitis C virus (HCV)-associated diffuse large B-cell lymphoma (DLBCL) through a comprehensive miRNAs expression profiling. Methods In this study, miRNA profiles were obtained from 37 patients with DLBCLs and 60 patients with reactive lymph nodes, equally distributed according to HCV presence. Germinal centres, from reactive lymph nodes were used as controls. Clinical features at presentation were available for all patients. Results A set of 52 miRNAs define a signature for HCV-associated DLBCL. Importantly, decreased expression of miR-138-5p and increased expression of miR-147a, miR-147b and miR-511-5p in HCV DLBCL was found to be a poor prognostic factor for HCV-positive DLBCL patients. Conclusions These data reveal molecular differences in diffuse DLBCL patients according to HCV presence, potentially useful as novel prognostic or therapeutic biomarkers.